Methylhydroxynandrolone was first described in 1964, developed during a series of investigations that looked at the effects of 4-hydroxylation on various nandrolone compounds. Being that 4-hydroxylation inhibits 5-alpha reduction, nandrolone derivatives with this alteration tend to be more androgenic. They are, therefore, less likely to cause side effects relating to low libido and reduced androgenicity, common with injectable nandrolone esters. Although early results showed that methylhydroxynandrolone was both effective and retained a favorable ratio of anabolic to androgenic effect, it was ultimately never developed into a medicine. Only MOHN's non-methylated cousin, oxabolone (as oxabolone cypionate), had reached the stage of prescription drug product. For approximately forty years after its synthesis, little mention was made of methylhydroxynandrolone in the medical literature. For all intents and purposes, it was a dead and forgotten anabolic steroid.
MOHN suddenly reemerged in 2004, when it was introduced as a "nutritional product" on the U.S. supplement market. It was being sold OTC, without the restrictions of a synthetic anabolic steroid. This was due primarily to the fact that it was never regulated as a drug in the U.S., and barring a direct listing in the 1991 Anabolic Steroid Control Act, could not be covered by it. Its legality as a supplement may have been questionable, but that was a matter for the FDA to handle, not the DEA (Drug Enforcement Agency). MOHN has since been included in the most recent expansion of U.S. anabolic steroid laws, however, and formally became a controlled anabolic steroid on January 20, 2005. Possession of this agent after this date carries all the same legal risks and consequences as other popular and illegal steroids according to Federal law. Due to the fact that it is not a prescription drug, this law effectively marked the commercial end of methylhydroxynandrolone products.
MOHN How Supplied
Methylhydroxynandrolone is not available as a commercial agent. When sold as a nutritional supplement, it generally contained 3mg of steroid per tablet.
Structural Characteristics MOHN
Methylhydroxynandrolone is a modified form of nandrolone. It differs by: 1) the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration and 2) the introduction of a hydroxyl group at carbon 4, which inhibits aromatization, progestational activity, and 5-alpha reduction, and reduces relative steroid androgenicity.
MOHN Side Effects (Estrogenic)
Methylhydroxynandrolone is not aromatized by the body, and is not measurably estrogenic. Estrogenic side effects such as increased water retention, fat gain, and gynecomastia are not likely to occur with use. The non-estrogenic nature of methylhydroxynandrolone makes this agent favorable during cutting or lean mass phases of training, when muscle definition is favored over raw bulk gains.
MOHN Side Effects (Androgenic)
Although classified as an anabolic steroid,androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss: Women are also warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. Additionally, the 5-alpha reductase enzyme does not metabolize methylhydroxynandrolone, so its relative androgenicity is not affected by finasteride or dutasteride.
MOHN Side Effects (Hepatotoxicity)
Methylhydroxynandrolone is a cl 7-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. Cl 7-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of cl 7-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain.
MOHN Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Although not studied in humans, the high relative potency, oral route, and non-aromatizable nature of methylhydroxynandrolone suggest that this agent is extremely prone to negatively altering lipid values and increasing atherogenic risk. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
MOHN Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
MOHN Administration (General)
Prescribing guidelines generally advise that oral steroids can be taken with or without meals. The difference in bioavailability is generally not regarded as substantial. However, a 2016 study on newborn infants did find the absorption of oxandrolone to be significantly improved when dissolved directly in fat (MCT oil). If the diet includes considerable fat content, taking this oral steroid with meals might be more advantageous.
MOHN Administration (Men)
Methylhydroxynandrolone was never approved for use in humans. Prescribing guidelines are unavailable. Effective oral daily doses for physique- or performance-enhancing purposes fall in the range of 2-10 mg. In an effort to reduce liver strain, it is usually recommended to limit drug duration to no longer than 6-8 weeks, after which point a break is taken from all c-17 alkylated steroids. At this level MOHN should provide very solid gains in lean muscle mass and strength, without water retention or increased fat deposition. MOHN is not thought of as a bulking drug itself, although is very versatile for stacking, and mixes well with many other anabolics depending on the individual goals of the user.
MOHN Administration (Women)
Methylhydroxynandrolone was never approved for use in humans. Prescribing guidelines are unavailable. The high anabolic to androgenic ratio of methylhydroxynandrolone makes use possible without significant virilization, but would likely require small doses (1-3mg per day) and respecting a very periodic use schedule (4 weeks or less).
Methylhydroxynandrolone is not available as a prescription agent at this time, in any part of the world.
Wlliam Llewellyn (2017) - Anabolics